Meinhard F. Schmidt Appointed Chairman of the Diabeloop Board

AlixPartners Forecasts: Household Products Could Cost U.S. Manufacturers and Consumers 15% More This Year Due to Resin Shortage

While companies can’t control the market forces at play, they can take action to mitigate the risk and impact of supply chain disruption.

How To Control a Radio Frequency (RF) Process

The radio frequency welding and manufacturing process uses electromagnetic energy and pressure to fuse and permanently bond vinyl, thermoplastic, and coated materials to produce a specific product - all according to customer requirements. Using this RF sealing process, a distinct, one-piece perpetual bond is formulated that is both solid and resistant to ripping or tearing. But how is this process controlled, and with what specific tools? Read on.

Meinhard F. SchmidtDiabeloop has appointed Meinhard F. Schmidt as its new non-executive chairman. Mr. Schmidt, a healthcare executive and entrepreneur with more than 25 years of international experience in the healthcare, diagnostics and medical devices industries, succeeds Dr. Guillaume Charpentier, who founded Diabeloop in 2015 and has held the position of Chairman since then.

“We are delighted to welcome Meinhard to the Board during this exciting time for Diabeloop,” says Erik Huneker, Diabeloop’s CEO. “With more than 25 years of experience in the global healthcare, diagnostics and medical device sector, he brings an invaluable international, industry, and corporate knowledge to the Company.”

Diabeloop is working on the european commercial deployment of its first product, the DBLG1TM System, an integrated device for autonomous diabetes management. The company is working on obtaining reimbursement agreements in France and Germany. The company, which is currently finalizing a second funding round, also plans to apply for FDA approval in the near future.

After Dr. Guillaume Charpentier stepped down as chairman of the board, Mr. Schmidt assumed this position on June 18, 2019. Dr. Charpentier will remain a member of the Board and Diabeloop Chief Medical Officer.

Dr. Guillaume Charpentier explains: “Bringing a project from an academic prototype to a marketed medical device that will have significant impact on patients’ lives, in less than 4 years, is a tremendous accomplishment for the Diabeloop team and its partners, the CEA-Leti* and the CERITD**. An ambitious task now awaits us to make this innovation available to all families living with Type One diabetes. Meinhard will help us through the next stages of our  development, to achieve our  ambitions.”

Meinhard F. Schmidt adds: “I was drawn to Diabeloop because it has all the hallmarks of a successful, commercial digital health company, including novel technology with the most advanced and promising closed-loop system. Diabeloop introduces an active intelligence layer in the traditional value chain of medical devices for diabetes treatment – something I was looking for since my 20 years of active engagement in the Diabetes Care industry. It’s a privilege to be joining the team at this important time and I am very excited about Diabeloop’s future and the difference we can make at a key phase of our transformation from a company focused on product development, to a full global acting commercial enterprise.”



Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.